diosmin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	3157	520-27-4

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

diosmin
barosmin
diosmil
diosmine
flebosten
flebosmil

A bioflavonoid that strengthens vascular walls.

Molecular weight: 608.55
Formula: C28H32O15
CLOGP: 0.23
LIPINSKI: 3
HAC: 15
HDO: 8
TPSA: 234.29
ALOGS: -2.60
ROTB: 7

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,ACVRL1,AURKA,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70	35
kinase-selectivity-class	AXL,CDK9,CHUK,GRK2,MAP2K6,MAP3K14,PDK1,PIK3CA,PIK3CD,PRKDC,ZAP70	11
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Tubulointerstitial nephritis and uveitis syndrome	66.77	21.98	10	1539	262	90626636
Erysipelas	63.14	21.98	17	1532	9035	90617863
Myoglobin blood increased	43.49	21.98	9	1540	1543	90625355
Hypercapnia	34.88	21.98	10	1539	6667	90620231
Delirium	30.23	21.98	20	1529	104339	90522559
Activated partial thromboplastin time prolonged	29.04	21.98	9	1540	7816	90619082
Hepatic encephalopathy	24.05	21.98	9	1540	13763	90613135
Thrombocytopenia	23.55	21.98	23	1526	208702	90418196
Drug interaction	23.21	21.98	26	1523	276427	90350471
Hepatitis acute	22.29	21.98	8	1541	10879	90616019

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood lactic acid	97.08	43.34	14	611	332	42620378

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood lactic acid	88.48	23.01	14	2140	464	110586681
Tubulointerstitial nephritis and uveitis syndrome	61.46	23.01	10	2144	396	110586749
Erysipelas	54.63	23.01	17	2137	13141	110574004
Myoglobin blood increased	38.09	23.01	10	2144	4222	110582923
Lentigo maligna	36.90	23.01	7	2147	675	110586470
Ventricular tachycardia	35.54	23.01	18	2136	49991	110537154
Hypercapnia	32.41	23.01	11	2143	11148	110575997
Lower respiratory tract congestion	23.32	23.01	7	2147	4789	110582356

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C05CA03	CARDIOVASCULAR SYSTEM VASOPROTECTIVES CAPILLARY STABILIZING AGENTS Bioflavonoids
ATC	C05CA53	CARDIOVASCULAR SYSTEM VASOPROTECTIVES CAPILLARY STABILIZING AGENTS Bioflavonoids
CHEBI has role	CHEBI:22586	antioxidant
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35842	antirheumatic drug
CHEBI has role	CHEBI:49201	anti-ulcer drug
CHEBI has role	CHEBI:67079	anti-inflammatory agent

Related Drugs by ATC class:

C05CA Bioflavonoids 4 drugs

hidrosmin monoxerutin rutoside troxerutin

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.73	acidic
pKa2	10.43	acidic
pKa3	12.32	acidic
pKa4	13.05	acidic
pKa5	13.7	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Lysine-specific histone demethylase 1A	Enzyme	O60341	KDM1A_HUMAN		IC50	4.99		CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit beta	Kinase	O14920	IKKB_HUMAN		IC50	5.41		CHEMBL

External reference:

ID	Source
N0000167025	NUI
D07858	KEGG_DRUG
4036523	VANDF
C0012498	UMLSCUI
CHEBI:4631	CHEBI
CHEMBL231884	ChEMBL_ID
D004145	MESH_DESCRIPTOR_UI
DB08995	DRUGBANK_ID
4370	INN_ID
7QM776WJ5N	UNII
5281613	PUBCHEM_CID
3489	RXNORM
005803	NDDF
126142004	SNOMEDCT_US
8143001	SNOMEDCT_US
7QM776WJ5N	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Bruselix Bruising	HUMAN PRESCRIPTION DRUG LABEL	8	59088-003	TABLET	200 mg	ORAL	unapproved drug other	10 sections